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Abstract
Background: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by surfactant accumulation,
and is caused by disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling. Abnormalities
in CSF2 receptor alpha (CSF2RA) were reported to cause pediatric hereditary PAP. We report here the first case of
CSF2RA-mutated, elderly-onset hereditary (h) PAP.
Case presentation: The patient developed dyspnea on exertion, and was diagnosed with PAP at the age of
77 years, based on findings from chest computed tomography scan and bronchoalveolar lavage. She tested
negative for GM-CSF autoantibodies, with no underlying disease. Her serum GM-CSF level was elevated (91.3 pg/
mL), indicating GM-CSF signaling impairment and genetic defects in the GM-CSF receptor. GM-CSF-stimulated
phosphorylation in signal transducer and activator of transcription 5 (STAT5) was not observed, and GM-CSF-Rα
expression was defective in her blood cells. Genetic screening revealed a homozygous, single-base C > T mutation
at nt 508—a nonsense mutation that yields a stop codon (Q170X)—in exon 7 of CSF2RA. High-resolution analysis of
single nucleotide polymorphism array confirmed a 22.8-Mb loss of heterozygosity region in Xp22.33p22.11,
encompassing the CSF2RA gene. She was successfully treated with whole lung lavage (WLL), which reduced the
serum levels of interleukin (IL)-2, IL-5, and IL-17, although IL-3 and M-CSF levels remained high.
Conclusions: This is the first known report of elderly-onset hPAP associated with a CSF2RA mutation, which caused
defective GM-CSF-Rα expression and impaired signaling. The analyses of serum cytokine levels during WLL
suggested that GM-CSF signaling might be compensated by other signaling pathways, leading to elderly-onset
PAP.
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Background
The lungs reduce alveolar surface tension by producing
pulmonary surfactants, which are essential for maintaining
smooth breathing. The levels of pulmonary surfactants are
balanced between their production by alveolar epithelial
cells and clearance by alveolar macrophages. Granulocyte/
macrophage colony-stimulating factor (GM-CSF), a 23-kDa
monomeric glycoprotein, regulates various functions of the
alveolar macrophages, including surfactant catabolism, and
plays an important role in pulmonary surfactant
homeostasis.
Pulmonary alveolar proteinosis (PAP) is a rare lung
disease characterized by the accumulation of surfactant
proteins, which causes progressive respiratory insuffi-
ciency [1–3]. Three clinically and etiologically distinct
forms of PAP are acknowledged: autoimmune, second-
ary, and congenital. More than 90% of PAP cases are
autoimmune type (aPAP). aPAP is specifically associated
with high levels of a neutralizing autoantibody against
GM-CSF that impairs GM-CSF-dependent surfactant
clearance mediated by alveolar macrophages [4–8].
The GM-CSF signal is conveyed through the GM-CSF
receptor on cell surfaces, via signal transducer and
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activator of transcription 5 (STAT5). The GM-CSF
receptor is a dodecameric complex consisting of a
ligand-specific alpha (GM-CSF-Rα, CD161) and a beta
(GM-CSF-Rβ, CD131) subunit, which is shared with the
interleukin (IL)-3 and IL-5 receptors [9, 10].
Recently, it has been reported that abnormalities in
the GM-CSF-Rα-encoding alleles (CSF2RA) cause
hereditary (h) PAP, presenting as insidious, progressive
dyspnea in children; and that increased serum GM-CSF
is useful to identify such individuals [11–15]. However,
no elderly-onset case with defect in the GM-CSF recep-
tor was reported until date. In the present report, we de-
scribe the oldest case of hPAP until date, whose
symptoms occurred at the age of 77. The patient
suffered severe hypoxemia, underwent a single whole
lung lavage (WLL), and showed dramatic improvement.
Methods
Measurement of GM-CSF autoantibody levels
The concentration of GM-CSF autoantibodies in the
bronchoalveolar lavage fluid (BALF) or serum were mea-
sured by sandwich enzyme-linked immunosorbent assay
(ELISA), performed as described previously [16, 17],
with slight modifications. In brief, 96-well microtiter
plates (Maxisorp, Nalge Nunc International, Rochester,
NY, U.S.A.) were coated with recombinant human (rh)
GM-CSF [1 μg/mL in phosphate-buffered saline (PBS)]
at 4 °C overnight, washed with PBS (containing 0.1%
Tween 20), and blocked with Stabilcoat (Surmodics,
Eden Prairie, MN, U.S.A.) at room temperature for 1 h.
The BALF sample was diluted to 1/100 (for patients with
PAP) in sample dilution buffer [PBS, 1% (w/v) goat
serum, 0.1% (v/v) Tween 20], and 50 μL of the diluted
sample was incubated in triplicate wells at room
temperature for 40 min. The plates were washed and
after addition of ammonium acetate (10 mM, pH 5.0),
incubated at room temperature for 15 min to prevent
non-specific binding. Next, horseradish peroxidase-
conjugated goat anti-human IgG (diluted to 1/3000 with
sample dilution buffer) was added, and the plates incu-
bated at room temperature for 30 min. Bound IgG was
detected using 3,3,5,5-tetramethylbenzidine substrate so-
lution (50 μL; Bethyl Laboratories, Montgomery, TX,
U.S.A.), followed by addition of 1 N H2SO4. The absorb-
ance was read at 450 nm using a microplate reader (Bio-
rad, Hercules, CA, U.S.A.).
Immunoblotting
Peripheral blood mononuclear cells (PBMCs) were cul-
tured on 24-well culture plates at 5 × 105 cells/well. The
cells were incubated with GM-CSF (0–1000 ng/mL) for
15 min. Lysed protein extracts were separated by sodium
dodecyl sulphate polyacrylamide gel electrophoresis,
transferred to a polyvinylidene fluoride membrane, and
assessed by standard western blotting procedures, as
previously described [5]. Primary antibodies used for
detection included anti-human GM-CSF-Rα (Santa Cruz
Biotechnology, Santa Cruz, CA, U.S.A.), GM-CSF-Rβc,
anti-human STAT5 (Santa Cruz Biotechnology) and
phospho (p)-STAT5 (Millipore, Billerica, MA, U.S.A.)
antibodies. Peroxidase-labeled anti-rabbit IgG antibody
(Sigma-Aldrich, St. Louis, MO, U.S.A.) was used as
secondary antibody and the bands were visualized with
ECL plus (GE Healthcare, Waukesha, WI, U.S.A.). To
enhance the signal, immunoreaction enhancer solution
(Can Get Signal, TOYOBO, Osaka, Japan) was used
according to the manufacturer’s instructions. Actin was
measured as loading control for each sample, using anti-
actin antibody (Santa Cruz Biotechnology).
Flow cytometry
Phosphorylated STAT5 detection by flow cytometry was
described previously [18]. Heparinized fresh whole blood
was incubated with 50 ng/mL rhGM-CSF and IL-2 for
20 min at 37 °C and fixed. Next, red blood cells were
lysed in Fix/Lyse buffer (BD Bioscience, Franklin Lakes,
NJ, U.S.A.) for 15 min at 37 °C. White blood cells were
collected by centrifugation and fixed in ice-cold metha-
nol at −20 °C for 1 h. After centrifugation, the cells were
suspended in 3% fetal bovine serum/0.01% NaN3/PBS
solution and incubated with Alexa Fluor 647-labeled
anti-pSTAT5 (BD Bioscience). Cells with phosphorylated
STAT5 were detected by flow cytometry (Cell Analyzer,
Sony, Tokyo, Japan).
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from blood mononuclear cells,
using RNA Easy Plus Mini Kit (QIAGEN, Hilden,
Germany), and was reverse transcribed with random
hexamer primers and the SuperScript III First-Stand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA,
U.S.A.). The cDNAs were subjected to semiquantitative
RT-PCR analysis with PrimerSTAR GXL DNA polymer-
ase (Takara Bio, Otsu, Japan) with CSF2RA-specific
primers (Additional file 1: Table S1).
Nucleotide sequencing
The PCR was performed to generate products spanning
exons and flanking sequences of the CSF2RA gene,
which were purified using the QIAquick DNA extraction
kit (QIAGEN) and subjected to nucleotide sequencing
using the BigDye Terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, U.S.A.) and
CSF2RA-specific primers (Supplementary Table). The
resulting sequences were compared with published
sequences for CSF2RA (GenBank/EMBL/DDBJ under
accession number NM_006140).
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Array-comparative genomic hybridization (aCGH)
aCGH analysis was performed using the CytoScan HD
array kit according to the manufacturer’s protocol (Affy-
metrix, Santa Clara, CA, U.S.A.). Genetic counseling was
performed for the patient before and after genetic
analyses.
Cytokine assay
IL-2, IL-3, IL-4, IL-5, IL-17, and M-CSF were analyzed
using ELISA kits (CUSABIO, Wuhan, Hubei Province,
P.R. China) according to the manufacturer’s protocol.
Case presentation
A previously healthy, 77-year-old, non-smoking woman,
with normal chest radiograph at a medical check-up
three years earlier, was referred to our hospital for dys-
pnea on exertion, which occurred one month earlier.
She was a homemaker with no remarkable family
history.
A physical examination revealed no abnormality. A
chest X-ray and computed tomography (CT) scan indi-
cated ground glass opacity in both lower lungs, of which
crazy-paving appearance was confirmed upon high-
resolution CT scan (Fig. 1a, b). Laboratory studies
revealed elevated levels of serum KL-6, a mucin-like pro-
tein (4314 U/mL), surfactant protein D (SP-D; 400 ng/
mL), and carcinoembryonic antigen (CEA; 13.2 ng/mL);
and negative test results for beta-D glucan and Aspergil-
lus antigen. Analysis of arterial blood gas while breathing
room air revealed a low partial pressure of oxygen
(PaO2) of 47 mmHg just before WLL. BALF presented a
milky appearance with lymphocytosis (macrophages,
64% of total cells; lymphocytes, 26%; neutrophils 9%;
eosinophils, 1%), foamy macrophages, and amorphous
materials (Fig. 1c, d).
The patient was diagnosed with PAP, based on typical
findings from chest CT scan and bronchoalveolar lavage.
She had no underlying disease. GM-CSF autoantibodies
were not detected in either the serum or the BALF. On
the other hand, a high level of serum GM-CSF was
detected (91.3 pg/mL), indicating disrupted GM-CSF
signaling and genetic defects in the GM-CSF receptor.
We decided to screen for GM-CSF signaling abnormal-
ities because GM-CSF concentration was extremely high
in her BALF.
To investigate signaling activated by GM-CSF in the
PBMCs, we first probed the presence of phosphory-
lated STAT5 upon stimulating the PBMCs with in-
creasing concentrations of GM-CSF (0–1000 ng/mL).
Phosphorylated STAT5 was observed in the control
but not in the patient PBMCs, indicating defective
GM-CSF signaling in the latter (Fig. 2). To confirm
this result, we performed flow cytometry. The results
also showed that expression of phosphorylated STAT5
was not observed on stimulation of peripheral blood
mononuclear cells of the patient with GM-CSF, while
expression of phosphorylated STAT5 was observed on
stimulation of those of the control with GM-CSF as
Fig. 1 a Chest radiogram of the patient. b High-resolution computed tomogram of the patient. c BALF presented a milky appearance with lymphocytosis
(26%). d Foamy macrophages and amorphous materials in BALF of the patient
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well as on stimulation of those of both with IL-2
(Fig. 3).
Next, we investigated the expression of the α and β
chains of the GM-CSF receptor on the PBMCs, by west-
ern blotting. The expression of GM-CSF-Rβ and IL-3Rα
on patient monocytes was comparable with that on the
controls; however, expression of GM-CSF-Rα was not
detected in the former (Fig. 4). The result was further
confirmed by RT-PCR (Fig. 5). Together, these results
indicated defects in the molecules that transmit GM-
CSF signals to STAT5.
cDNAs of CSF2RB, reverse-transcribed from the
mRNA of the patient PBMCs, harbored no mutations or
deletions (data not shown). PCR amplicons for each
exon of CSF2RA from the patient PBMCs were screened
for their nucleotide sequences, revealing a homozygous
single-base mutation C > T at nt 508 in exon 7 (Fig. 6).
This mutation was a nonsense mutation that gave rise to
a stop codon (Q170X).
Further evaluation by aCGH demonstrated a 22.8-Mb
region of loss of heterozygosity (LOH) in Xp22.33p22.11,
encompassing the CSF2RA gene.
To investigate the functional background underlying
the late onset of the symptoms in the present case, we
compared the changes in serum levels of IL-2, IL-3, IL-
4, IL-5, IL-17, and M-CSF before and after WLL that
improved PaO2 by 26 mmHg (Fig. 7). The IL-2, IL-4,
and IL-5 levels were remarkably reduced post WLL,
Fig. 2 Granulocyte/macrophage colony-stimulating factor (GM-CSF)-
stimulated phosphorylation of signal transducer and activator of
transcription 5 (STAT5) in peripheral blood mononuclear cells (PBMCs) of
the patient. PBMCs from either the patient or a normal control subject
were incubated with different concentrations of GM-CSF (0–1000 ng/
mL). Phosphorylated (p) STAT5 was detected by western blotting. Total
STAT5 (STAT5) and actin levels were examined as positive controls
Fig. 3 Flow cytometry analysis for the expression of phosphorylated STAT5 upon stimulation of peripheral blood mononuclear cells of the
patient (left) and a control (right) with interleukin (IL)-2 and granulocyte/macrophage colony-stimulating factor (GM-CSF)
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after which they gradually increased. IL-17 levels
remained low for about 7 months after WLL. On the
other hand, IL-3 and M-CSF levels were marginally al-
tered post WLL. In addition, the serum level of GM-CSF
demonstrated a tendency to decrease after WLL.
Discussion
The present study reports the first case of elderly-onset
hPAP with CSF2RA mutation. The patient had a
homozygous mutation that changed a codon for glutam-
ine 170 to a stop codon, disrupting normal expression of
GM-CSF-Rα and proper signaling of GM-CSF. We pre-
viously reported a case of adult-onset hPAP that was due
to homozygous nonsense mutation in the CSF2RB gene
[15]. The present case, where the patient developed
hPAP in her seventies, is the oldest until date for this
disease (Table 1). Interestingly, her mutation was in exon
Fig. 4 a Detection of granulocyte/macrophage colony-stimulating factor receptor alpha (GM-CSFRα; upper panel), and actin (lower panel) in
peripheral blood monocytic cells of the patient (PBMCs) (left), and a control (middle), by western blotting with specific antibodies. GM-CSF-Rα
was not detected in the patient (left lane) but was observed for the control (middle lane). b Detection of GM-CSFRβ (upper panel) and actin
(lower panel) in PBMCs of the patient (left), and a control (right), by western blotting with specific antibodies. Bands for GM-CSF-Rβ and actin
were detected for both the patient and the control
Fig. 5 Reverse transcription polymerase chain reaction for mRNA
obtained from peripheral blood mononuclear cells of the patient
and a normal control, using primers specific for CSF2A, CSF2B, IL3RA,
and ACTB
Fig. 6 Nucleotide sequence of the CSF2RA gene, encoding nt 502–516
(numbered relative to the initiation codon; GenBank/EMBK/DDBJ
accession no. NM_006140), from the patient and a normal control
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7 of the CSF2RA gene, in which the first child case for
hPAP also had a mutation [11].
To investigate the background of the late-onset hPAP
in this case, we studied her serum profile for various
cytokines. The patient was treated with WLL, which
greatly improved oxygenation indices and reduced the
serum levels of various cytokines including IL-2, IL-5,
and IL-17, indicating relieved inflammatory activation of
Th1 and Th17 lymphocytes. In contrast, the serum levels
of IL-3 and M-CSF remained high after WLL, indicating
that they might be needed even after the treatment pro-
cedure. The high activities of IL-3 and M-CSF in the pa-
tient might be associated with the clinical course of her
late-onset hPAP.
It is notable that GM-CSF, IL-3, IL-4, and IL-5 are coded
by neighbor genes located at 5q31.1, and affect the func-
tions of monocytes and macrophages. The serum levels of
IL-4, IL-5, and GM-CSF decreased after WLL, while IL-3
levels remained high. Receptors of IL-3 and IL-5 share beta
chains with that of GM-CSF. Disruption of the alpha chain
of the GM-CSF receptor might affect stoichiometry of the
common beta chains, presumably causing substantial alter-
ations in IL-3 and IL-5 signaling. Interestingly, WLL differ-
entially affected the levels of these cytokines in the serum
of the patient in this study.
Similar to previous pediatric hPAP cases, the present
case also demonstrated a high level of serum GM-CSF
and a good response to WLL (Table 1). The increased
serum GM-CSF levels might be useful for identifying pa-
tients with childhood as well as adult hPAP [19, 20]. The
present case showed remarkable response to WLL with
regard to oxygenation indices and serum levels of vari-
ous cytokines that might be associated with compensa-
tion of GM-CSF signaling.
Conclusions
This is the first known report of elderly-onset hPAP
associated with a genetic defect in CSF2RA, which caused
defective GM-CSF-Rα expression and impaired signaling.
These results suggest that GM-CSF signaling is
Fig. 7 Analysis of cytokine profile of the patient before and after whole lung lavage, by enzyme-linked immunosorbent assay for interleukin (IL)-2,
IL-3, IL-4, IL-5, IL-17, M-CSF, and GM-CSF
Table 1 Clinical characteristics of reported cases of hereditary
pulmonary alveolar proteinosis
Present case Tanaka et al. Junne et al.
Characteristics Adult onset Adult onset Juvenile (n = 20)




Prognosis Good Poor Good




Mutated gene CSF2RA CSF2RB CSF2RA




GM-CSF granulocyte/macrophage colony-stimulating, ND not detected, CSF2RA,
CSF2 receptor alpha, CSF2RB, CSF2 receptor beta, WLL whole lung lavage
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compensated by other signaling pathways, leading to
elderly-onset or non-symptomatic PAP.
Additional file
Additional file 1: Table S1. A list of primers for PCR and sequencing.
(DOCX 17 kb)
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